OVERVIEW

The adrenergic drugs affect receptors that are stimulated by Norepinephrine or epinephrine. (Sympathetic)

Sympathomimetic: adrenergic drugs that act directly on the adrenergic receptor (adrenoceptor) by activating it.

Sympathomimetics have similar effects to the Norepinephrine

Other drugs affect adrenergic function by interrupting the release of Norepinephrine from adrenergic neurons.

This chapter describes agents that either directly or indirectly stimulate the adrenoceptor (Figure 6.1).

MAO: an enzyme in the mitochondria of the neurons that oxidized the monoamine (NE), then NE is converted into an inactive metabolite such as vanillylmandelic acid (VMA). This can be used to indicate if the body is secreting huge amounts of NE.

In the vesicles of the adrenal gland, the NE is converted into epinephrine.

Reserpine prevents the uptake of Dopamine; this will lead to its degradation,

Thus, Reserpine was used to treat blood pressure, cuz it dec. NE release – thus dec. BP

Quanethidine and bretylium prevent the release of NE.

Cocaine or will prevent the reuptake of the NE, this lead to the accumulation of NE in the synapse – more activation is produced -- Will inc. the sympathetic effects.

Tricyclic-antidepressants the same as cocaine but with Dopamenergic neurons.

Adrenergic receptors

In general, receptors are divided into types and subtypes according to their affinities to different agonists and antagonists and according to gene cloning.

Adrenergic receptors: two main receptor types: α and β.

α-adrenergic receptors are subdivided into α1 and α2.

β-adrenergic receptors are subdivided into β1, β2, & β3.

α-receptors

For α-receptors, the rank order of potency is:

Epinephrine ≥ Norepinephrine >> Isoproterenol ……………….?

This means that we need lower doses of NE or Epin. Than Isoproterenol, to produce the same effects.

α1-receptors have a higher affinity for Phenylephrine than do α2-receptors.

α2-receptors have a higher affinity for clonidine than do α1-receptors.

(A) α1-receptors exist on postsynaptic membranes of effecter organs as smooth muscles of blood vessels.

Activation of α1-receptors causes constriction of smooth muscles.

Activation of α 1 receptors initiates a series of reactions through a G-protein activation of

phospholipase C, resulting in the generation of IP3 from phosphatidylinositol, causing the release of Ca from

the endoplasmic reticulum into the cytosol2 (Figure 6.5).

Signal transduction (mechanism) for α1-receptors is through activation of PLC (phospholipase C) pathway

(as in M1 & M3-receptors).

(B). α2-receptors:

These receptors, located primarily on presynaptic nerve endings and on the β-cells of the pancreas, to control the output of NE & insulin,

When a sympathetic adrenergic nerve is stimulated, the released Norepinephrine traverses the synaptic cleft

and interacts with the α1-receptors.

A portion of the released Norepinephrine “circles back” and reacts with the

α2-receptors on the neuronal membrane (see Figure 6.5). The stimulation of the α2-receptors causes feedback

inhibition of the ongoing release of Norepinephrine from the stimulated adrenergic neuron.

This inhibitory action decreases further output from the adrenergic neuron and serves as a local modulating

mechanism for reducing sympathetic neuromediator output (NE) when there is high sympathetic activity.

Signal transduction for α2-receptors, In contrast to a1 receptors, the effects of binding at α2-receptors are

mediated by inhibition of adenylyl cyclase and a fall in the levels of intracellular cAMP (such as M2 R.)

β-receptors

For β1-receptors, the rank order of potency is:

Isoproterenol > epinephrine = Norepinephrine

For β2-receptors:

Isoproterenol > epinephrine > Norepinephrine

Signal transduction for β1 & β2-receptors is through activation of adenylate cyclase, and therefore increased concentrations of cAMP within the cell.

Distribution of receptors:

Adrenergically innervated organs and tissues tend to have a predominance of one type of receptor.

For example, tissues such as the vasculature to skeletal muscle have both α1 and β2 receptors, but the β2 receptors predominate.

Other tissues may have one type of receptor exclusively, with practically no significant numbers of other types of adrenergic receptors.

For example, the heart contains predominantly β1 receptors.

Smooth muscles of blood vessels in the skeletal muscles have β2-receptors and are therefore sensitive to epinephrine released from adrenal medulla.

They also have some α1-receptors, but β2-receptors predominate.

Smooth muscles of blood vessels in the skin & abdominal viscera have predominantly α1-receptors.

Cardiac muscles have mainly β1-receptors.

Bronchial smooth muscles have predominantly β2-receptors.

NE effects according to the receptors

Smooth M of bronchi

relaxation

Heart

Contraction

B.V of skeletal M

Relaxation

B.V of Skin

contraction

Desensitization of receptors

Prolonged exposure of a receptor to its agonist reduces the responsivity of these receptors to the agonist.

In other words, the effect of the agonist fades down.

This phenomenon is called receptor desensitization.

There are 3 mechanisms for desensitization:

1) Sequestration of receptors so that they are unavailable for interaction with ligand.

2) Receptor down-regulation: decrease in number of receptors on cell surface due to receptor destruction & decreased synthesis.

3) Inability to couple to G-protein due to phosphorylation of receptor on the cytoplasmic side.

For example, β-receptors are phosphorylated by either protein kinase A or β–adrenergic receptor kinase.

(βARK).

CHARACTERISTICS OF ADRENERGIC AGONISTS (Sympathomimetics)

Most of the adrenergic drugs are derivatives of β -phenylethylamine (Figure 6.7).

Individual agents differ in the substitutions on the benzene ring and the amine group.

Sympathomimetics or adrenomimetics are subdivided in term of MOA into:

(1) Direct acting. (2)Indirect acting. (3) Mixed (direct & indirect).

Sympathomimetics are subdivided in term of structure into:

(1) Catecholamines: compounds that contain catechol group

(2) Non-Catecholamines: compounds that do not contain catechol group

Catecholamines

These are the Sympathomimetics that contain the catechol group:

Catecholamines include, (Al are direct acting)

Epinephrine, natural

Norepinephrine, natural

Isoproterenol, synthetic compound

Dopamine, natural

Dobutamine, synthetic compound

Catecholamines have the following properties:

(a) Highly potent in activating α &/or β -receptors. That is small doses perform high response.

(b) Rapidly inactivated by MAO (in neurons, liver, & gut wall [GIT]) & COMT (in synapses & gut wall). Therefore, they have a short duration of action and ineffective if administered orally.

(c) Penetration into CNS is poor. This is because they are polar. (Two OH groups).

Still they sometimes produce CNS side effects like anxiety & headache.

Non-Catecholamines

These compounds lack one or both of the hydroxyl groups of the catechol.

Non-Catecholamines include,

(1) Direct acting:

Albuterol,

Clonidine,

Metaproterenol,

Methoxamine,

Phenylephrine,

ritodrine,

Terbutaline.

(2) Indirect-acting:

Amphetamine

Tyramine,

(3) -mixed (direct & indirect):

Ephedrine,

Metaraminol.

Non-catecholamine have the following properties:

a) Longer duration of action than Catecholamines because they are not inactivated by CQMT.

b) Lower potency than Catecholamines.

c) Better penetration into CNS than Catecholamines. Higher lipophilicity, lower -OH

Mechanism of action of adrenergic agonists.

1. Direct-acting agonists:

These drugs act directly on α or β receptors,

They produce effects similar to those that occur following stimulation of sympathetic nerves or release of the

hormone epinephrine from the adrenal medulla (Figure 6.8).

Examples of direct-acting agonists include epinephrine, norepinephrine, isoproterenol, and phenylephrine.

2. Indirect-acting agonists:

These agents, which include amphetamine and tyramine, are taken up into the presynaptic neuron and cause the

release of norepinephrine from the cytoplasmic pools or vesicles of the adrenergic neuron (see Figure 6.8).

As with neuronal stimulation, the norepinephrine then traverses the synapse and binds to the α or β receptors.

3. Mixed-action agonists:

Some agonists, such as ephedrine and metaraminol, have the capacity both to directly stimulate adrenoceptors

and to release norepinephrine from the adrenergic neuron (see Figure 6.8).

IV. DIRECT-ACTING ADRENERGIC AGONISTS

catecholamines

Direct-acting agonists bind to adrenergic receptors without interacting with the presynaptic neuron.

The activated receptor initiates synthesis of second messengers and subsequent intracellular signals.

As a group, these agents are widely used clinically.

[1] Epinephrine [ep ee NEF rin]

It is one of five catecholamines, commonly used in therapy.

Epinephrine is synthesized from tyrosine in the adrenal medulla and released, along with small quantities of norepinephrine, into the blood stream.

Epinephrine interacts with both α & β receptors.

The dose determine whether α or β will be stimulated.

At low doses, effects on β-receptors predominates Vasodilatation

At high doses, effects on α-receptors predominates Vasoconstriction

[[ 1 ]] Actions of Epinephrine

(1) On cardiovascular:

The major actions of epinephrine are on the cardiovascular system.

1. It increases contractility of the myocardium

(positive isotropic: β1 action)

2. It Increases myocardium rate of contraction

(positive chronotropic: β1 action).

3. Cardiac output therefore increases.

4. With these effects, come increased oxygen demands on the myocardium.

5. It constricts arterioles in the skin, mucous membranes,

and viscera-including kidneys (α effects).

6. It dilates vessels going to the liver and skeletal muscle (β2 effects).

7. Renal blood flow is decreased.

8. The cumulative effect, therefore, is an increase in systolic blood pressure,

coupled with a slight decrease in diastolic pressure

(Figure 6.9) that can result in a reflex slowing of the heart.

(2) Respiratory:

Epinephrine causes powerful bronchodilation by acting directly on bronchial smooth muscle (β2 action).

This action relieves all known allergic- or histamine-induced bronchoconstriction.

In the case of anaphylactic shock, this can be life saving.

In individuals suffering from an acute asthmatic attack, epinephrine rapidly relieves the dyspnea (labored

breathing) and increases the tidal volume (volume of gases inspired and expired).

(3) Blood sugar:

Epinephrine has a significant hyperglycemic effect because it

Increases glycogenolysis in liver (β2 effect),

Increases release of glucagon (β2 effect),

In addition, decreases release of insulin (α2 effect).

These effects are mediated via the cyclic AMP mechanism.

(4) Lipolysis:

Epinephrine initiates lipolysis

through its agonist activity on the β receptors of adipose tissue,

which upon stimulation, activate adenylyl cyclase to increase cyclic AMP levels.

Cyclic AMP stimulates a hormone-sensitive lipase,

which hydrolyzes triacylglycerols to free fatty acids and glycerol.

[[ 2 ]] Biotransformations:

Epinephrine, like the other catecholamines, is metabolized by two enzymatic pathways:

COMT and MAO (see Figure 6.3).

The final metabolites found in the urine are metanephrine, vanillylmandelic acid, and Normetanephrine.

[[ 3 ]] Therapeutic uses:

(1) Bronchospasm:

Epinephrine is the primary drug used in the emergency treatment of any condition of the respiratory tract.

Epinephrine is the drug of choice In treatment of acute asthma and anaphylactic shock,

within a few minutes after subcutaneous administration, greatly improved respiratory exchange is observed.

Administration may be repeated after a few hours.

However, selective β2 agonists, such as terbutaline, are presently favored in the chronic treatment of asthma

because of a longer duration of action and minimal cardiac stimulatory effect.

(2) Glaucoma:

It causes vasoconstriction of the ciliary body blood vessels,

thus it reduces the production of aqueous humor,

thus it is used topically to reduce intraocular pressure in open-angle glaucoma.

(3) Anaphylactic shock:

Epinephrine is the drug of choice for the treatment of Type I hypersensitivity reactions in response to

allergens.

(4) with local anesthetics:

Local anesthetic solutions usually contain 1:100,000 parts epinephrine.

The effect of the drug is to greatly increase the duration of the local anesthesia.

It does this by producing vasoconstriction at the site of injection, thereby allowing the local anesthetic to

persist at the site before being absorbed into the circulation and metabolized.

Very weak solutions of epinephrine (1:100,000) can also be used topically to vasoconstrict mucous

membranes to control oozing of capillary blood.

[[ 4 ]] Pharmacokinetics:

Epinephrine has a rapid onset but brief duration of action.

In emergencies epinephrine is given intravenously for the most rapid onset of action;

It may also be given subcutaneously, by endotracheal tube, by inhalation, or topically to the eye.

Oral administration is ineffective, since epinephrine and the other catecholamines are inactivated by

intestinal enzymes.

Only metabolites are excreted in the urine.

[[ 5 ]] Adverse effects:

(1) CNS disturbances:

Epinephrine can produce adverse CNS effects that include anxiety, fear, tension, headache, and tremor.

(2) Hemorrhage:

The drug may induce cerebral hemorrhage due to elevation of blood pressure.

(3) Cardiac arrhythmias:

Epinephrine can trigger cardiac arrhythmias; particularly if the patient is receiving digitalis.

(4) Pulmonary edema:

Epinephrine can induce pulmonary edema.

[[ 6 ]] Interactions:

(1) Hyperthyroidism:

Hyperthyroidism increases the density of adrenergic receptors

Lead to an increased sensitivity of tissues to Epinephrine. (hypersensitive response)

Thus, we need to reduce Epinephrine dose

(2) Cocaine:

In the presence of cocaine, epinephrine produces exaggerated cardiovascular actions.

This is due to the ability of cocaine to prevent re-uptake of catecholamines into the adrenergic neuron;

Thus, like norepinephrine, epinephrine remains at the receptor site for longer periods of time (see Figure 6.3).

[2] Norepinephrine (NE) [nor ep ee NEF nfl]

Since norepinephrine is the neuromediator of adrenergic nerves,

It should theoretically stimulate all types of adrenergic receptors.

In practice, when the drug is given in therapeutic doses to humans, the α-adrenergic receptor is most affected.

Thus norepinephrine Affects α -receptors mostly.

[[ 1 ]] Actions of Epinephrine

(1) Cardiovascular Actions.

a. Vasoconstriction:

NE causes vasoconstriction of most vascular beds (including kidneys – dec. renal blood flow)

Result in a rise in peripheral resistance.

Thus, both systolic and diastolic blood pressures increase (Figure 6.10).

(2) Baroreceptor reflex:

In isolated cardiac tissue, NE stimulates cardiac contractility;

In vivo, vasoconstriction increases blood pressure

This will induce the Baroreceptor reflex

Rise in increased vagal activity.

This cause bradycardia

This bradycardia counteracts direct stimulatory effects on the heart (Figure 6.10).

(3) Effect of atropine pretreatment:

If atropine (which blocks the transmission of vagal effects) is given before NE,

then NE stimulation of the heart will lead to tachycardia.

[[ 2 ]]Therapeutic uses:

Norepinephrine is used to treat shock.

Because it increases vascular resistance and, therefore, increases blood pressure;

However, dopamine is better, because it does not reduce blood flow to the kidney as does epinephrine.

NE is never used for asthma.

Note: When norepinephrine is used as a drug, it is sometimes called levarterenol [leev are TER a nole].

[3] Isoproterenol

[eye soe proe TER a nole]

It is a direct-acting synthetic catecholamine

Stimulates both β1 and β2 adrenergic receptors.

Its non-selectivity is one of its drawbacks.

Its action on α-receptors is insignificant.

[[ 1 ]] Actions of Isoproterenol

(1) Cardiovascular: (Figure 6.11).

Isoproterenol produces intense stimulation of the heart

to increase its rate and force of contraction,

Causing increased cardiac output

and slightly increased systolic BP.

It is as active as epinephrine in this action

it is useful in the treatment of atrioventricular block or cardiac arrest.

Isoproterenol also dilates the arterioles of skeletal muscle (β2)

Resulting in a decreased peripheral resistance.

and in a strong decreased diastolic blood pressure.

(2) Pulmonary:

The drug produces a strong and rapid bronchodilation

(β2 action, Figure 6.12).

Isoproterenol is as active as epinephrine

Rapidly alleviates an acute attack of asthma,

When taken by inhalation (which is the recommended route).

This action lasts about one hour.

[[ 2 ]] Therapeutic uses of Isoproterenol

To stimulate heart in cases of atrioventricular block or cardiac arrest.

[[ 3 ]] Pharmacokinetics:

Isoproterenol can be absorbed systemically by the sublingual mucosa

But is more reliably absorbed when given parenterally

or as an inhaled aerosol.

It is a marginal substrate for COMT and is stable to MAO action.

[[ 4 ]] Adverse effects:

Isoproterenol adverse effects are similar to those of epinephrine.

[4] Dopamine

[DOE pa meen]

Produced in the brain as a neurotransrnitter in the basal ganglia.

[[ 1 ]] Actions of Dopamine.

Dopamine activates α & β . and D1 & D2- dopamine receptors.

(1) Cardiovascular:

Dopamine exerts a stimulatory effect on the β1 receptors of the heart,

having both inotropic and chronotropic effects (Figure 6.12).

At very high doses, dopamine activates α-receptors on the

vasculature, resulting in vasoconstriction.

Low doses: stimulation of heart through β1-receptors. ---- Increased systolic BP.

High doses: vasoconstriction through a1-receptors.

(2)Renal and visceral:

Dopamine dilates renal and splanchnic arterioles by activating dopaminergic receptors,

thus increasing blood flow to the kidneys and other viscera (see Figure 6.12).

These receptors are not affected by α or β-blocking drugs.

Therefore, dopamine is clinically useful in the treatment of shock,

in which significant increases in sympathetic activity might compromise renal function.

[Note: Similar dopamine receptors are found in the autonomic ganglia and in the CNS.]

- Vasodilatation in mesenteric & renal arterioles through dopamine receptors ----- increased renal blood flow.

Diastolic BP is not affected significantly.

D2-receptors are inhibitory heteroreceptors on presynaptic adrenergic neurons - - - - - -

activation of these D2-receptors decreases NE release from these neurons.

[[ 2 ]] Therapeutic uses of Dopamine

Shock: (include a very low pressure as a complication)

Dopamine is the drug of choice for shock.

It is given by continuous infusion.

It raises the blood pressure by stimulating the heart (β1 action).

In addition, it enhances perfusion to the kidney and splanchnic areas, as described above.

An increased blood flow to the kidney enhances the glomerular filtration rate and causes sodium diuresis.

In this regard, dopamine is far superior to norepinephrine,

which diminishes the blood supply to the kidney and may cause kidney shutdown.

[5] Dobutamine

Actions

Dobutamine [doe BYOO ta meen]

It differs from dopamine in two things, 1) it is synthetic. 2) it is β1 -receptor agonist.

Thus it Increases heart rate & contractility - - - - - - increases cardiac output.

Does not have significant vascular Effects, cuz it doesn’t effect α-R and not β2-R that much.

Therapeutic uses of Dobutamine

Dobutamine increases cardiac output in congestive heart failure,

without increasing oxygen demand of the heart.

This is a major advantage over other sympathomimetics,

which increase oxygen demand.

Adverse effects of Dobutamine

Generally same as Epinephrine

Use with caution in atrial fibrillation.

Because dobutamine increases atrioventricular conduction.

-Tolerance may develop on prolonged use.

In the atrial fibrillation we have many impulses in the aria that we don’t want these impulses to go down to the ventricles, if dobutamine is given, it will inc. the conduction velocity in the AV node which will transmit all of those impulses to the ventricles, thus we don’t use dobutamine in such cases.

IV. DIRECT-ACTING ADRENERGIC AGONISTS

non-catecholamines

[6] Phenylephrine

Phenylephrine is Synthetic selective agonists of α1- receptor.

Since it is not a catechol derivative, it is not inactivated by COMT- long duration of action.

Actions

Causes vasoconstriction.

Thus, it will increase the peripheral vascular resistance.

Therefore, if phenylephrine is given parenterally, it increases both systolic & diastolic blood pressures,

and produces reflex bradycardia without affecting the heart directly. “Baroreflex”

Therapeutic uses

(1) As decongestant ---- given topically on the nasal mucous membranes.

Nasal Congestion

when the person get infection, the body start releasing substances that perform vasodilatation, which in turn

increases the spaces in the blood vessels causing the liquids to be releases in large amounts than usual. This is the congestion.

Thus in this case a vasoconstrictor as Phenylephrine is uses.

(2) To produce mydriases (for retinal examination) ------ as an ophthalmic solution.

(3) To raise the blood pressure. “Especially in the sudden B.P fall cases such as the pregnant women)

(4) For paroxysmal supraventricular tachycardia

These patient having a sudden increase in the heat rate, phenylephrine will cause vasoconstriction

then it initiates the baroreflex then the brain will cause the hare to slow down.

Adverse effects

Hypertensive headache, anything that constrict or dilates the blood vessels in the brain will cause the headache.

Cardiac irregularities, if given to a normal person who’s H-R is normal

[7] Methoxamine

It is a Synthetic selective agonists of α1- receptor

Actions

Causes vasoconstriction

Therapeutic uses

1) For paroxysmal supraventricular tachycardia

2) It is used to raise BP during surgery that involves halothane anesthetics without inducing arrhythmia

the halothane that are used during surgery, causes the fall in the B-P and arrhythmia,

the drugs that used to inc. the B-P usually exaggerate the arrhythmia,

thus the Methoxamine is usful since it inc. the B-P without inc. the arrhythmia.

Adverse effects

Hypertensive headache,

vomiting.

[8] Clonidine

Synthetic selective agonists of α2- receptor

(α1- receptor occur in the 1-pancreases dec. insulin, and 2-presynaptically dec. NE, and in the CNS )

Central activation of α2-receptor inhibits sympathetic vasomotor discharge ------ decreases BP

Therapeutic uses

For treatment of hypertension.

To minimize symptoms of withdrawal from opiates or benzodiazepines.

[8] Methyldopa

Reduces the B.P

As with Clonidine, methyldopa exerts a hypotensive effect through activating central α2-receptor.

[9] Apraclonidine & Brimonidine

Lower intraocular pressure ----- - for the treatment of glaucoma.

these drugs causes vasoconstriction in the ciliary body, thus it decreases the formation of the intraocular fluid

Cholinomimetic inc. the drainage from the eye.

Sympathomimetics decrease the formation into the eye.

[10] Ometazoline

Synthetic agonists of both α1 & α1-receptors

A topical decongestant (α1-effect).

[11] Metaproterenol

It is a synthetic selective agonist on β2 Receptor,

Causes bronchodilation with only little effect on the heart.

Used for the treatment of asthma ------ - administered orally or by inhalation.

[12] Terbutaline

More selective to β2-receptors than Metaproterenol

Therapeutic uses

For the treatment of asthma

To reduce uterine contractions -------- suppress premature labor (may delay labor for several days).

It works on the β2 receptors on the uterine muscle, causing its relaxation.

[13] Albuetrol

Used for the treatment of asthma (inhalation).

[13] Retodrine

Used to reduce uterine contractions.

[13] Salmeterol & Formoterol

Long-acting bronchodilators.

These two drugs are used for the prevention from the asthma ( prophylaxes ), because they have long duration of action.

Pleasure = dopamine

Mental stimulation = NE

V. INDIRECT-ACTING ADRENERGIC AGONISTS

These drugs do not activate adrenergic receptors directly, they do not act on receptors

but cause accumi1ation of NE in the synapse ---- - increased adrenergic transmission.

[1] Amphetamine

Many analogues of amphetamine have been synthesized.

Amphetamine is related to a natural alkaloid, cathinone, which is found in the leaves of khat (القات).

Ingesting khat results i the same effects of taking amphetamine.

Amphetamine acts centrally & peripherally increasing the release of catecholamines. esp. NE & dopamine ---

mental stimulation & pleasure.

Peripherally, amphetamine increases BP due to vasoconstriction & increased cardiac output.

Therapeutic uses:[ treatment of]

1) Depression.

2) Attention-deficit hyperactivity children.

3) Narcolepsy.

4) To suppress appetite.

Should be avoided in pregnancy because it impairs the development of the fetus.

[2] Tyramine

A natural compound present in fermented food like ripe cheese.

MAO normally metabolizes tyramine in the liver

If the patient having depression, he takes MAO inhibitor, (to prevent the destruction of NE and dopamine)

If Tyramine administered with food having MAO inhibitor,

this lead to the accumulation of tyramine,

this will inc. the release of NE,

this lead to serious vasopressor episode. (Very high contractions in the blood vessels). And inc. the C.O.

this lead to a sudden high increase in the blood pressure

MOA: tyramine enters adrenergic nerve terminals and displaces stored NE- the displaced NE is released to the synapse and activates adrenergic receptors.

[3] Cocaine

A local anesthetic with central effects similar to those of amphetamine

MOA: inhibits the reuptake of NE & dopamine from the adrenergic & dopaminergic synapses in the CNS.

It is heavily abused

Mixed-action sympathomimetics

These drugs do two things:

1) Directly activate postsynaptic adrenergic receptors.

2) Cause accumulation of NE in synapse -------- increased adrenergic transmission.

[1] Ephedrine

A natural compound.

Found in Ma-huang, a popular herbal medication.

Has been used in China for> 2000 years.

A1so produced synthetically.

Releases NE from adrenergic nerves

and stimulates both α & β -receptors

produces effects similar to those of epinephrine. (not selective, not medically important)

Ephedrine is less potent than epinephrine,

but has a longer duration of action because it is not catecholamine

thus it is a poor substrate for COMT & MAO.

Oral absorption is excellent.

Penetrates the BBB.

Thus it affect the CNS.

Ephedrine increases cardiac output (β1) & causes vasoconstriction (α1)

Hence raises systolic & diastolic BP

(Remember that epinephrine increases systolic but decreases diastolic BP).

Ephedrine produces bronchodilation. (β2)

Therapeutic uses: [declining due to availability of newer more potent agents with fewer adverse effects]

1) Ephedrine is slower and less potent than epinephrine & isoproterenol in producing bronchodilation.

However, it has a longer duration of bronchodilator effect.

Therefore, ephedrine is not used to treat acute attacks of asthma,

but in prophylaxis against the asthmatic attack.

2) increases alertness & decreases fatigue. (these happen from any drug that inc. NE)

3) improves athletic performance.

4) nasal decongestant (due to the local vasoconstrictor effect). As phenylephrine

5) To raise BP.

Pseudo-ephedrine (one of the four ephedrine enantiomers)

It is included in many decongestant preparations.

It has also been used for treatment of stress incontinence in women.

MOA: the sympathetic stimulation does urinary retention.

[1] Metaraminol

It is used in the treatment of shock and acute hypotension

Enhances cardiac activity & produces mild vasoconstriction.

* * * * All above-mentioned non-catecholamines can be administered orally * * * *

Because if the MAO acted on them they will not be destructed cuz, they are not catecholamines.

Some adverse effects observed with sympathomimetics in general.

1) Cardiac arrhythmias

Tachycardia (β1) or bradycardia (baroreflex)

2) Headache

3) Hyperactivity.

4) Insomnia (inability to sleep)

5) Nausea.

6) Tremors.

By three mechanisms

Diffusion to the blood.

2. Reuptake by

transporter.

inactivation by

COMT

Different transporters

… Synthesis and release of Norepinephrine from the adrenergic neuron …

In adrenal medulla. On stimulation, adrenal

medulla releases 85% E & 15% NE.

Lipid to fatty acids so it can be used in gluconeogenesis,

= Retention of the urine

= β3 too

In skeletal muscles

Skin & viscera

Glycogen

to glucose

Counter regulatory hormone, inc. Gluconeogenesis

No Ch3 on the amine group = NOR

It has isopropyl group = isopro

They differ among each other’s in the substitution

on the amine group.

Increased selectivity to β -receptors

The substitution on the amine group determines selectivity to β - receptors:

Phenylephrine & Ephedrine are poor substrates for MAO – prolonged duration of action

Catecholamine

Non-Catecholamine

Conduction velocity decreases.

Conduction velocity increases.

PAGE

- 14 -